Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Barinthus Biotherapeutics Plc ADR (BRNS)

Barinthus Biotherapeutics Plc ADR (BRNS)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.0500 unch (unch) 03/28/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.0500 unch (unch) 15:49 ET
Quote Overview for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.0201
Day High
1.0500
Open 1.0250
Previous Close 1.0500 1.0500
Volume 6,400 6,400
Avg Vol 11,205 11,205
Stochastic %K 54.38% 54.38%
Weighted Alpha -53.38 -53.38
5-Day Change +0.0600 (+6.06%) +0.0600 (+6.06%)
52-Week Range 0.8008 - 4.1591 0.8008 - 4.1591
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,239
  • Shares Outstanding, K 40,228
  • Annual Sales, $ 14,970 K
  • Annual Income, $ -61,070 K
  • EBIT $ -65 M
  • EBITDA $ -59 M
  • 60-Month Beta -0.80
  • Price/Sales 2.82
  • Price/Cash Flow N/A
  • Price/Book 0.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.34
  • Number of Estimates 2
  • High Estimate -0.30
  • Low Estimate -0.37
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +15.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9300 +12.90%
on 03/04/25
Period Open: 1.0100
1.1400 -7.89%
on 03/14/25
+0.0400 (+3.96%)
since 02/28/25
3-Month
0.9112 +15.23%
on 01/14/25
Period Open: 1.0600
1.2800 -17.97%
on 01/03/25
-0.0100 (-0.94%)
since 12/27/24
52-Week
0.8008 +31.12%
on 12/12/24
Period Open: 2.3800
4.1591 -74.75%
on 04/04/24
-1.3300 (-55.88%)
since 03/28/24

Most Recent Stories

More News
Q1 Virtual Investor Summit: On-Demand Presentations Now Live

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors...

SNANF : 0.1900 (unch)
BRNS : 1.0500 (unch)
FEMY : 1.2900 (-3.37%)
PERF : 1.6900 (+0.60%)
DRTS : 2.56 (-3.76%)
GIFT : 2.17 (+3.33%)
ROYIF : 0.0202 (-51.21%)
ZCAR : 4.13 (-14.42%)
CLNN : 3.22 (+1.26%)
MIND : 5.89 (-4.07%)
PYPD : 2.74 (+0.74%)
TOVX : 1.1400 (-5.79%)
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11

NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bill Enright, CEO and Gemma Brown, CFO of Barinthus Biotherapeutics plc, will be presenting at this year's Investor Summit Virtual on March 11th.

BRNS : 1.0500 (unch)
Barinthus Biotherapeutics Announces Geoffrey Lynn, M.D., Ph.D. as New Chief Scientific Officer

Barinthus Biotherapeutics appoints Geoffrey Lynn as Chief Scientific Officer, succeeding Nadège Pelletier effective December 1, 2024.Quiver AI SummaryBarinthus Biotherapeutics plc has announced the promotion...

BRNS : 1.0500 (unch)
Barinthus Biotherapeutics Reports Significant Phase 2b HBV003 Trial Findings, Highlighting HBsAg Loss and Functional Cure Potential

Eight participants in the HBV003 trial achieved HBsAg loss; two met functional cure criteria. Results to be presented on November 18, 2024.Quiver AI SummaryBarinthus Biotherapeutics announced promising...

BRNS : 1.0500 (unch)
Arbutus Biopharma and Barinthus Bio Report Promising HBsAg Loss Results in Phase 2a IM-PROVE II Clinical Trial for Chronic HBV Infections

New data shows significant HBsAg declines in chronic hepatitis B patients treated with imdusiran, VTP-300, and low-dose nivolumab.Quiver AI SummaryArbutus Biopharma Corporation and Barinthus Biotherapeutics...

BRNS : 1.0500 (unch)
Fed Speaks, Canada Inflation on Lineup Next Week

Monday U.S. Economic Lookahead Home builder confidence index (Feb.) Featured Earnings ...

AOT.TO : 0.1100 (-4.35%)
FLOW.TO : 0.1150 (unch)
SMT.TO : 0.79 (-5.95%)
DD : 74.03 (-2.54%)
CNM : 48.50 (-2.86%)
HQY : 86.96 (-2.11%)
HUMA : 1.9600 (-2.49%)
BRNS : 1.0500 (unch)

Business Summary

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases. The company's product pipeline includes VTP-300, VTP-200, VTP-1000, VTP-850 and VTP-1100. Barinthus...

See More

Key Turning Points

3rd Resistance Point 1.0899
2nd Resistance Point 1.0699
1st Resistance Point 1.0600
Last Price 1.0500
1st Support Level 1.0301
2nd Support Level 1.0101
3rd Support Level 1.0002

See More

52-Week High 4.1591
Fibonacci 61.8% 2.8762
Fibonacci 50% 2.4799
Fibonacci 38.2% 2.0837
Last Price 1.0500
52-Week Low 0.8008

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies